If you are suffering from schizophrenia, you may benefit from participating in one of our clinical trials, which offer you treatment with novel substances that have not yet reached market approval and can therefore not be prescribed otherwise.
Regarding schizophrenia, we are currently performing the following clinical trials:
An adaptive, phase IIB/III, multi-center, prospective, randomized, double-blind, placebo-controlled study of the safety and efficacy of NaBen® (sodium benzoate), a D-amino acid oxidase inhibitor, as an add-on treatment for schizophrenia in adults.
You might consider study participation if the following inclusion criteria apply:
Duration of Study: up to 68 weeks
We will gladly discuss further in- and exclusion criteria as well as study procedures during a personal meeting.
An adaptive phase II/III, double-blind, randomized, placebo controlle, two-part, dose-finding, multi-center study of the safety and efficacy of NaBen® (sodium benzoate), a D-amino acid oxicdase inhibitor, as an add-on therapy with clozapine, for residual symptoms of refractory schizophrenia in adults.
You might consider study participation if the following inclusion criteria apply:
Duration of Study: 12 weeks
We will gladly discuss further in- and exclusion criteria as well as study procedures during a personal meeting.
For further information, please contact our site staff:
Dinah Schramm, telephone number: 06131-17-6101,
dinah.schramm@unimedizin-mainz.de
and/or
Ricarda Endler, telephone number: 06131-17-6102,
ricarda.endler@unimedizin-mainz.de
or
or get in touch with us via our general e-mail address:
SPE@unimedizin-mainz.de
University Medical Center Mainz
Study Center for Clinical Trials in Mental Disorders
Untere Zahlbacher Str. 8
55131 Mainz
Germany